MeiraGTx Q2 net income $160.7M; bota-vec acquired, $400M Oberland deal, BTD for AAV2-hAQP1

MeiraGTx Holdings plc

Q2 net income $160.7M ($1.76 basic EPS) vs net loss $38.8M in Q2 2025; revenue from services and licenses surged.
Completed $25M acquisition of bota-vec (XLRP) from J&J; $100M equity financing; up to $400M Oberland investment with $375M non-dilutive.
FDA granted Breakthrough Therapy Designation for AAV2-hAQP1; Phase 2 AQUAx2 enrollment completed; 3-year data positive.
Lilly collaboration: $75M upfront, up to $400M milestones for medu-vec and gene therapy tech; also $95M due from Hologen.
Cash $145.4M at June 30, 2026; expects runway into H2 2028.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.